Evidence map›Paper›PMID 29228761›Full record

ArticleOncotarget2017

Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.

Laura F Hutchins, Issam Makhoul, Peter D Emanuel, Angela Pennisi, Eric R Siegel, Fariba Jousheghany, Xueyan Guo, Anastas D Pashov, Behjatolah Monzavi-Karbassi, Thomas Kieber-Emmons

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Therapeutic vaccines for breast cancer: Has the time finally come?European journal of cancer (Oxford, England : 1990) · 2022
    Review
  12. Review
  13. Novel classes of immunotherapy for breast cancer.Breast cancer research and treatment · 2022
    Review
  14. Article
  15. Article
  16. Article
  17. Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2021
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Laura F HutchinsDepartments of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Issam MakhoulDepartments of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Peter D EmanuelDepartments of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Angela PennisiDepartments of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Eric R SiegelDepartments of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Fariba JousheghanyDepartments of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Xueyan GuoDepartment of Gastroenterology, Third Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Anastas D PashovStephan Angelov Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Behjatolah Monzavi-KarbassiDepartments of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Thomas Kieber-EmmonsDepartments of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
University of Arkansas for Medical Sciences · USWinthrop Rockefeller Foundation · USShaanxi Provincial People's Hospital · CNStephan Angeloff Institute of Microbiology · BG

Funding

Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021
$21.5M
Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
NCATS NIH HHS UL1 TR000039NIGMS NIH HHS P20 GM103625
6 · The paper itself

Abstract

Tumor-associated carbohydrate antigens (TACAs) support cell survival that could be interrupted by anti-TACA antibodies. Among TACAs that mediate cell survival signals are the neolactoseries antigen Lewis Y (LeY) and the ganglioside GD2. To induce sustained immunity against both LeY and GD2, we developed a carbohydrate mimicking peptide (CMP) as a surrogate pan-immunogen that mimics both. This CMP, referred to as P10s, is the N-terminal half of a peptide vaccine named P10s-PADRE, the C-terminal half of which (PADRE) is a Pan-T-cell epitope. A Phase I dose-escalation trial of P10s-PADRE plus adjuvant

Indexed as

breast cancercancer vaccineclinical trialpeptide mimotopestumor-associated carbohydrate antigens

Identifiers

PMID29228761
PMCPMC5716801
OpenAlexW2765283598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.